Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?
Børset, Magne; Elsaadi, Samah; Vandsemb, Esten Nymoen; Hess, Eli Svorkdal; Steiro, Ida Johnsen; Cócera Fernández, Miguel; Sponaas, Anne-Marit; Abdollahi, Pegah
Peer reviewed, Journal article
Published version
![Thumbnail](/ntnu-xmlui/bitstream/handle/11250/3062955/B%25C3%25B8rset%2bet%2bal%2bEuropean%2bJ%2bof%2bHaematology%2b-%2b2022%2b-%2bHighly%2bexpressed%2bgenes%2bin%2bmultiple%2bmyeloma%2bcells%2b%2b%2bwhat%2bcan%2bthey%2btell%2bus%2babout.pdf.jpg?sequence=6&isAllowed=y)
Åpne
Permanent lenke
https://hdl.handle.net/11250/3062955Utgivelsesdato
2022Metadata
Vis full innførselSamlinger
Sammendrag
Cancer cells can convert proto-oncoproteins into oncoproteins by increasing the expression of genes that are oncogenic when expressed at high levels. Such genes can promote oncogenesis without being mutated. To find overexpressed genes in cancer cells from patients with multiple myeloma, we retrieved mRNA expression data from the CoMMpass database and ranked genes by their expression levels. We grouped the most highly expressed genes based on a set of criteria and we discuss the role a selection of them can play in the disease pathophysiology. The list was highly concordant with a similar list based on mRNA expression data from the PADIMAC study. Many well-known “myeloma genes” such as MCL1, CXCR4, TNFRSF17, SDC1, SLAMF7, PTP4A3, and XBP1 were identified as highly expressed, and we believe that hitherto unrecognized key players in myeloma pathogenesis are also enriched on the list. Highly expressed genes in malignant plasma cells that were absent or expressed at only a low level in healthy plasma cells included IFI6, IFITM1, PTP4A3, SIK1, ALDOA, ATP5MF, ATP5ME, and PSMB4. The ambition of this article is not to validate the role of each gene but to serve as a guide for studies aiming at identifying promising treatment targets.